Research Article

MicroRNA-25 Protects Smooth Muscle Cells against Corticosterone-Induced Apoptosis

Bin Zhang,1,2 Gaoxing Zhang,1,2 Tianlu Wei,3 Zhen Yang,2,4 Wenfeng Tan,1,2 Ziqing Mo,1,2 Jinxue Liu,1,2 Dong Li,2,5 Yidong Wei,6 Lukun Zhang,7 Keith A. Webster,8 and Jianqin Wei9

1Department of Cardiovascular Disease, The Jiangmen Central Hospital, Jiangmen 529030, China
2Clinical Experimental Center, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-Sen University, Jiangmen 529030, China
3Department of Medicine, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China
4Department of Cardiovascular, Sun Yat-Sen University, Guangzhou 510080, China
5Department of Intensive Care Unit, The Jiangmen Central Hospital, Jiangmen 529030, China
6Youjiang Medical University for Nationalities, Chengxiang Rd, Baise, Guangxi 533000, China
7Department of Infection, Third People’s Hospital of Shenzhen, 29 Bulan Road, Shenzhen 518112, China
8Department of Molecular and Cellular Pharmacology and the Vascular Biology Institute, Miller School of Medicine, University of Miami, FL 33136, USA
9Department of Medicine, Division of Cardiology, Miller School of Medicine, University of Miami, FL 33136, USA

Correspondence should be addressed to Jianqin Wei; jwei@med.miami.edu

Received 19 September 2018; Revised 17 December 2018; Accepted 1 January 2019; Published 12 March 2019

Guest Editor: Jaideep Banerjee

Copyright © 2019 Bin Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Aims. Vascular smooth muscle cells (VSMCs) are central components of atherosclerotic plaque. Loss of VSMCs through apoptotic cell death can cause fibrous cap thinning, necrotic core formation, and calcification that may destabilize plaque. Elevated glucocorticoid levels caused by psychological stress promote VSMC apoptosis and can exacerbate atherosclerosis in mice and humans. Changes in the levels of antiapoptosis microRNA-25 (miR-25) have been linked with heart disease, inflammation, VSMC phenotype, oxidative stress, and apoptosis. Here, we investigated the pathways and mechanisms of glucocorticoid-induced apoptosis of mouse VSMCs and the protective role of miR-25.

Methods. Primary mouse VSMCs were cultured +/- corticosterone for 48 h. Apoptosis, ROS, apoptotic protein activities, miR-25, MOAP1, a miR-25 target, and p70S6 kinase were quantified at intervals. The roles of miR-25 were assessed by treating cells with lenti-pre-miR-25 and anti-miR-25.

Results. VSMC apoptosis, caspase-3 activity, and Bax were increased by corticosterone, and cell death was paralleled by marked loss of miR-25. Protection was conferred by pre-miR-25 and exacerbated by anti-miR-25. Pre-miR-25 conferred reduced expression of the proapoptotic protein MOAP1, and the protective effects of pre-miR-25 were abrogated by overexpressing MOAP1. The antiapoptotic effects of miR-25 were paralleled by inhibition of the p70S6K pathway, a convergence target for the survival signaling pathways, and protection by pre-miR-25 was abrogated by the p70S6k inhibitor rapamycin. Conclusions. MicroRNA-25 blocks corticosterone-induced VSMC apoptosis by targeting MOAP1 and the p70S6k pathway. Therapeutic manipulation of miR-25 may reduce atherosclerosis and unstable plaque formation associated with chronic stress.

1. Introduction

Glucocorticoids are anti-inflammatory, immune-suppressive hormones that contribute importantly to the regulation of glucose metabolism and blood homeostasis. They are released from the adrenal gland at various stages of development and in adults especially during occupational stress exposure. Because of their anti-inflammation properties, glucocorticoids have clinical applications in the treatment of pain associated with inflammation and a range of conditions that involve overactive immune systems such as transplantation, allergy, and autoimmune disease. Glucocorticoids are also...
used to enhance the therapeutic effects of diuretics and natriuretic peptides in patients with advanced heart failure. Obviously, more chronic clinical use of glucocorticoids are limited by their potentially serious adverse side effects [1–3].

Epidemiological studies support roles for elevated glucocorticoid levels in exacerbating coronary artery disease risk and progression associated with psychological stress, especially occupational stress in humans and environmental stress in rodents [4–7]. Cortisol is the major glucocorticoid of humans, whereas the rodent equivalent is corticosterone. The relationships between environmental stress, glucocorticoids, and atherosclerosis; their molecular and cellular signaling pathways; and their mechanisms of interaction are poorly understood.

VSMCs play pivotal roles in atherogenesis including initiation, progression, and stability of plaques [8]. Phenotypic switching, abnormal proliferation, and turnover of VSMCs are components of plaque growth and expansion as well as stability of mature plaques. VSMC apoptosis in particular can influence plaque stability by causing fibrous cap thinning, necrotic core formation, and calcification. VSMC apoptosis is induced by proinflammatory cytokines, oxidized low-density lipoprotein, and mechanical injury [9, 10]. Glucocorticoid-induced VSMC apoptosis has been recognized for 2 decades, although the targets and mechanisms are still unclear.

Multiple noncoding RNAs known as microRNAs (miRs) have been reported to control VSMC turnover and apoptosis [11–13]. For example, miR-21, miR-26a, miR-29b, and miR-126 have been variously reported to regulate the balance between VSMC apoptosis and proliferation in different vascular tissues while miR-143 and miR-145 confer growth regulation by determining phenotypic switching [11–13]. Targets for such miRs include growth factor pathway intermediates, ROS production, transcription factors, cell cycle, and/or apoptosis control points.

miR-25 is part of the miR-106b/25 cluster located on chromosome 7q22 of the host maintenance protein 7 (MCM7), a gene that is highly conserved in vertebrates [14]. MCM7 is a component of the MCM2–7 complex of DNA helicases that are required for the initiation of DNA replication in eukaryotic cells [14–17]. miR-25 has 1163 predicted target mRNA transcripts (TargetScanHuman version 7.1) and can target mRNAs involved in DNA damage, cell cycle regulation, cell proliferation, migration, and differentiation under physiological as well as pathological conditions (reviewed in [18]). It has been implicated in the development and spread of many tumor types and shown to confer important regulation of apoptosis, autophagy, oxidative stress, inflammation, and calcium handling. As such, miR-25 is implicated in the pathogenesis of multiple conditions including but not limited to acute myocardial infarction, heart failure, diabetes, nephropathies, cerebral ischemia/reperfusion injury, neurodegenerative diseases, schizophrenia, and multiple sclerosis (reviewed in [18]). Direct cell signaling pathway targets for miR-25 include FOXO3a, SOCS4, SOX4, RGS3, NOX4, Cyclin E2, Smad7, PKC, Krüppel-like factor 4 (KLF4), ERK, PTEN, and WNT/β-catenin [19–25]. In cancer cells, miR-25 was shown to target the proapoptotic protein MOAP1 while its antiapoptosis protective effects in other cell types have been linked with activation of the PTEN/Akt and AMPK signaling pathways [26]. Other studies documented protective roles for miR-25 in osteoblast responses to dexamethasone [27].

Here, we sought to investigate roles for miR-25 in the responses of VSMCs to treatment with the glucocorticoid corticosterone. We show that the increased rate of apoptosis of VSMCs caused by corticosterone is mediated by ROS, downregulation of miR-25, and enhanced expression of proapoptotic protein MOAP1. Protection was afforded by overexpression of miR-25 and exacerbated by anti-miR-25 or MOAP1 overexpression. Corticosterone activated the p70 ribosomal protein S6 kinase 1 (S6K1) pathway in a miR-25-dependent manner, and corticosterone-dependent apoptosis was significantly alleviated by rapamycin, a selective S6K1 inhibitor.

2. Materials and Methods

2.1. Reagents. Antibodies were obtained from the following vendors: anti-caspase-3, cleaved caspase-3, BCL2, GAPDH, and pp-70S6K from Cell Signaling Technology; anti-Bax from Santa Cruz; anti-MOAP1, corticosterone, and rapamycin from Sigma; and human pre-microRNA expression construct lenti-pre-miR-25 and anti-miR-25 from System Biosciences LLC.

2.2. Smooth Muscle Cell Culture and Treatment. C57BL/6 mouse primary aortic smooth muscle cells (Cell Biologics) were cultured as previously described [28–31]. Corticosterone and rapamycin were added to the culture media at 30 ng/mL and 25 nM/mL, respectively. Cells were infected with lentivirus as described previously [32].

2.3. Measurement of ROS Productions. ROS were measured using an OxiSelect ROS assay kit from Cell Biolabs, San Diego, as described by the manufacturer.

2.4. Cell Apoptosis Assay. Apoptosis was analyzed by TUNEL assay using a Click-IT® Plus TUNEL Assay Kit (Life Technologies Inc.) and was performed according to the manufacturer’s instructions. TUNEL-positive nuclei of six nonoverlapping fields per coverslip were counted by a researcher blinded to treatment, and these counts were converted to percentages by comparing the TUNEL-positive counts to the total number of cell nuclei as determined by DAPI counterstaining: TUNEL − positive ratio = (number of red nuclei + number of blue nuclei) × 100%.

2.5. Luciferase Reporter Assay. Luciferase assays were performed as previously described [33]. Forty-eight hours after transfection, cell extracts were assayed for luciferase activity using a Luc-Pair miR luciferase assay kit (GeneCopoeia). Relative reporter activities were expressed as luminescence units normalized to Renilla luciferase activity. Luminescence was quantified using a multimode microplate reader (BMG Labtech).

2.6. Quantitative RT-PCR. Total RNA was isolated from myocardial tissue using TRIzol reagent and analyzed by
qRT-PCR using TaqMan probes (Applied Biosystems, Foster City, CA, USA) as described previously [34–37]. The miR-25 primers were Fw 5′-CGG CGG CAT TGC ACT TGG TCT C-3′ and Rv 5′-GTG CAG GGT CCG AGG T-3′. Primers for detection of MOAP1 mRNA were Fw TGA ACC CTC GGA AAG CG and Rv TTC TCA TCC CTC CTG AAC ATC. miRNA quantifications are presented as ratio of miRNA/5S-rRNA.

**Figure 1:** Increased ROS and apoptosis by corticosterone treatment. VSMCs were treated with corticosterone. Reactive oxygen species (ROS) were measured using an OxiSelect ROS assay kit and expressed as relative light units (RLU) (a). Apoptosis was detected by TUNEL assay (b, c). Results are expressed as mean ± S.E.M. **p < 0.01.** PBS-24 and PBS-48 h: VSMCs were treated with PBS 24 and 48 hours; Corti-24 h and Corti-48 h: VSMCs were treated with corticosterone as indicated for 24 and 48 hours.

**Figure 2:** Corticosterone induces expression of apoptosis-associated proteins in VSMCs. VSMCs were treated with corticosterone. Western blot analyses show expression of Bax (a), cleaved caspase-3 (b), and Bcl-2 (c); bands on western blot depict Bax, cleaved caspase-3, Bcl-2, and GAPDH. Results are expressed as mean ± S.E.M. **p < 0.01.** PBS-24 and PBS-48 h: VSMCs were treated with PBS for 24 and 48 hours; Corti-24 h and Corti-48 h: VSMCs were treated with corticosterone for 24 and 48 hours.
2.7. Western Blot. Our procedures for western blotting are described in detail elsewhere [38]. Briefly, 40 μg of protein was separated by 12% SDS-PAGE and transferred onto nitrocellulose, blocked with 5% fat-free skim milk in TBS containing 0.05% Tween 20 (1 h at room temperature), and incubated with antibodies overnight at 4°C. Protein bands were visualized by ECL detection reagent.

2.8. Statistical Analysis. Data are expressed as mean ± S.E.M. Statistical comparisons were performed using ANOVA followed by paired, one-tailed t-test, using InStat software for Macintosh (GraphPad Software Inc.).

3. Results

3.1. Induction of ROS and Apoptosis in VSMCs by Corticosterone. As shown in Figure 1(a), ROS production increased by 5.9- and 6.7-fold in VSMCs treated with corticosterone for 24 h and 48 h, respectively (both p < 0.01). Apoptotic indices increased in parallel by 21.34% and 24.67% in the corticosterone treatment groups compared with 6.24% and 6.56% in controls (p < 0.01), determined by TUNEL staining (Figures 1(b) and 1(c)). Western analyses confirmed significantly increased levels of Bax (2.4- and 3.5-fold; p < 0.01), cleaved caspase-3 (2.6- and 3.5-fold; p < 0.01), and decreased Bcl-2 (2.6- and 3-fold; p < 0.01), at each time point, shown in Figures 2(a)–2(d). These results confirm that corticosterone promotes apoptosis of VSMCs by the intrinsic, mitochondrial pathway.

3.2. Downregulation of miR-25 in VSMCs by Corticosterone Treatment. MicroRNA-25 levels were quantified by qRT-PCR after culture of VSMCs in the presence and absence of corticosterone for 24 or 48 hours as described in Materials and Methods. We found that miR-25 levels were decreased by 63.2% and 59% (both p < 0.01) after 24 and 48 hours, respectively, of corticosterone treatment (Figure 3(a)).

3.3. Corticosterone Induces Expression of MOAP1 in VSMCs. MOAP1 mRNA expression in VSMCs groups ± corticosterone as indicated above was determined using qRT-PCR. As expected, MOAP1 levels increased significantly by 2.1- and 2.3-fold (both p < 0.01) after 24 h and 48 h of treatment, as shown in Figure 3(b). Western blots further revealed
that MOAP1 protein increased in parallel by 2.3- and 2.6-fold (both \( p < 0.01 \)) at the 24 h and 48 h treatment times, as shown in Figures 3(c) and 3(d). These results demonstrate that corticosterone induced increased expression of MOAP1 in VSMCs in parallel with the apoptotic pathway described in Figure 1.

3.4. MOAP1 Is a Target of miR-25. It was reported recently that miR-25 can target MOAP1 mRNA in lung cancer cells [26]. Our studies confirmed the presence of an RNA-binding site for miR-25 in the 3′-UTR of the MOAP1 gene (Figure 4(a)) and suggest that the MOAP1 transcript is a direct target of miR-25. To test for functional regulation of apoptosis by miR-25 through a MOAP1 target, we infected VSMCs with lentiviral vectors expressing pre-miR-25 or antagomiR-25. Infection with pre-miR-25 caused a significant decrease in MOAP1 expression at both mRNA and protein levels, whereas transfection with antagomiR-25 caused a marked increase, consistent with miR-25 targeting of MOAP1 mRNA (Figures 4(b)–4(d)). Also consistent with a miR-25-MOAP1 interaction at the 3′-UTR, we found that a luciferase reporter construct with a mutant MOAP1 3′-UTR was not responsive to pre-miR or anti-miR-25 coinfection (Figure 4(e)). These results suggest that MOAP1 is a direct target of miR-25 in VSMCs consistent with previous work on lung cancer cells [26].

3.5. miR-25 Attenuates Oxidative Stress and Apoptosis by Targeting MOAP1 in VSMCs. VSMCs were infected with lentiviral vectors expressing pre-miR-25 or antagomiR-25 and subjected to 24 h culture ± corticosterone as described in Figure 1. Expression of miR-25 was increased 5.8-fold by lenti-pre-miR-25 and decreased by 49.5% for antagomiR-25 (Figure 5(a)). TUNEL analysis revealed apoptotic indices of 6.78% in control cultures without treatments, 22.15% in the corticosterone plus antagomiR-25 group, and 10.23% in the corticosterone plus pre-miR-25 group (all \( p < 0.01 \)) (Figure 5(b)). The results confirm that overexpression of miR-25 inhibits corticosterone-induced apoptosis in VSMCs. To confirm a role for MOAP1, VSMCs were transfected with plasmid pcDNA-MOAP1 and cultured ± corticosterone for 24 hours. We found that pre-miR-25 suppressed endogenous expression of MOAP1 in VSMCs and this was reversed in the pcDNA-MOAP1 treatment group (Figures 6(a) and 6(b)). Notably, pcDNA-MOAP1 significantly abrogated the effects of pre-miR-25 on both apoptosis and ROS production (Figures 6(c) and 6(d)). These results confirm that miR-25 protects VSMCs from corticosterone-induced cellular injury by targeting MOAP1.

3.6. miR-25 Inhibits p70S6K Activity Coincident with Decreased MOAP1 Expression in Corticosterone-Treated VSMCs. Crosstalk between the miR-25 and survival signaling pathways has been reported [11, 21, 26, 39]. Multiple such
pathways converge on Akt and p70S6K. Therefore, we investigated a possible crosstalk between miR-25 and p70S6K in VSMCs treated with corticosterone (Figure 7). As expected, phosphorylated p70S6K (p-p70S6K) was increased in VSMCs by corticosterone (Figure 7(a)). When VSMCs were infected with pre-miR-25, corticosterone-induced p-p70S6K levels decreased while the reverse was observed in the antagomiR-25 cotreatment group (Figure 7(b)). To further investigate the relationship between miR-25 and p70S6K in this system, we treated VSMCs with rapamycin, a selective p70S6K inhibitor ± corticosterone, and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterone-induced apoptosis was partially blocked by rapamycin, whereas protection was significantly greater in the presence of both corticosterone and antagomiR-25. As shown in Figure 7(c), apoptosis was differentially blocked by rapamycin. Corticosterin

3.7. Discussion. Our studies show that physiological levels of corticosterone stimulate ROS production and apoptosis of cultured VSMCs. Corticosterone activated the mitochondrial intrinsic apoptotic pathway, and the effects were paralleled by markedly decreased miR-25 and activation of the MOAP1 and p70S6K pathways. Overexpression of miR-25 during exposure to corticosterone blocked apoptosis and inhibited both MOAP1 and p70S6K. The effects were abrogated by overexpression of MOAP1 or cotreatment with rapamycin. This is the first study to link glucocorticoid-activated apoptosis with miR-25, MOAP1, and the p70S6K signaling pathway. The results provide a mechanism for the role of psychological stress in exacerbating atherosclerosis and may provide new therapeutic avenues for its management.

Regulatory roles for multiple miRNAs in the progression of apoptosis, glucocorticoid actions, oxidative stress, and VSMC biology are well described [13, 19–25, 40–44]. Accumulating evidence indicates that miR-25 confers antiapoptotic functions in multiple cell and tissue types by targeting different genes and pathways. miR-25 was reported to inhibit apoptosis in lung cancer by targeting RGS3 and MOAP1 [22]. Roles for miR-25 in blocking apoptosis caused by oxidative stress of cardiac H92C and kidney tubule cells have been reported, and in one study, miR-25 was shown to target NOX4, thereby regulating NADPH oxidase activity [24, 25, 39]. The antiapoptosis roles, targets, and regulation of miR-25 are tissue-specific [24, 39, 45, 46]. Our work indicates that in VSMCs, glucocorticoid exposure mediates a downregulation of miR-25 that parallels increased ROS and this prevents the antiapoptosis functions of miR-25, a conclusion that is consistent with previous work [39]. Overexpression of miR-25 by infection of cells with lenti-pre-miR-25 fully
restored miR-25 levels and prevented the proapoptotic actions of corticosterone.

MOAP1 promotes caspase-dependent apoptosis by binding proapoptotic BAX via its Bcl-2 homology-3- (BH3-) like domain. MOAP1 is rapidly upregulated in response to multiple apoptotic stimuli [40, 46, 47]. Our findings are consistent with previous work that MOAP1 is a direct target for miR-25. We propose that miR-25-dependent downregulation of MOAP1 is the principal avenue of protection against corticosterone-induced injury of VSMCs. We also found that miR-25 overexpression conferred increased levels of protective Bcl2, whereas p70S6K was repressed, and the effects were reversed by antagomiR-25. p70S6K is a member of the IGF-1 and PI-3 kinase signaling pathways that include Akt and mTOR intermediates. Stimulation of these pathways usually confers a growth response but can also regulate apoptosis and autophagy by crosstalk with other pathways. In our study, we found that p70S6K phosphorylation was increased by treatment of VSMCs with corticosterone in parallel with increased ROS and decreased miR-25. Although causal roles for S6K1 in the regulation cannot yet be confirmed, such roles would be consistent with its activation by breakdown of miR-25 and repression by pre-miR (Figure 7(c)). A negative role of S6K1 in this pathway is also supported by the overriding effects of rapamycin on corticosterone-induced apoptosis.

4. Conclusion

We present novel observations that glucocorticoid treatment of VSMCs represses the expression of miR-25 while increasing ROS production, activity of S6K1, and apoptotic index. Overexpression of miR-25 reversed these effects. We propose that regulation of MOAP1 by miR-25 is the central mechanism and such signaling by corticosterone may be associated with ROS and S6K1. The study has direct implications to the established proatherogenic effects of psychological stresses including those associated with the occupational environment, which are known to be accompanied by increased levels of glucocorticoids. MicroRNA-25 is a potential therapeutic target that may ameliorate the plaque-destabilizing effects of glucocorticoid-induced apoptosis of VSMCs in advanced atherosclerosis disease.
4.1. Limitations of the Study. We acknowledge that these studies are limited to mouse VSMCs treated with the murine glucocorticoid hormone corticosterone and do not necessarily fully mimic human VSMCs treated with cortisol. The experiments are also limited to cultured cells and may not accurately reflect the actions or pathways driven by these glucocorticoid hormones in vivo. Therefore, additional experiments are required for the results to be considered relevant to humans or clinical pathologies.

Data Availability

All the data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

BZ, GZ, and TW did the experiment, data analysis, and manuscript preparation; WT, ZM, JL, DL, YW, and LZ did the experiment preparation; and ZY, KAW, and JQW did the experimental design, data analysis, interpretation, and manuscript preparation. Bin Zhang, Gaoxing Zhang, and Tianlu Wei contributed equally to this work.

Acknowledgments

This study was supported by the National Natural Scientific Foundation of China (81670220 to ZY and RO1 HL109582 and HL072924 to KAW).

References

[1] P. J. Barnes, “Glucocorticoids,” Chemical Immunology and Allergy, vol. 100, pp. 311–316, 2014.
[2] P. J. Bray, B. du, V. M. Mejia et al., “Glucocorticoid resistance caused by reduced expression of the glucocorticoid receptor in cells from human vascular lesions,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 5, pp. 1180–1189, 1999.
[3] A. Achuthan, A. S. M. Aslam, Q. Nguyen et al., “Glucocorticoids promote apoptosis of proinflammatory monocytes by inhibiting ERK activity,” Cell Death & Disease, vol. 9, no. 3, article 267, 2018.
[4] H. Bosma, M. G. Marmot, H. Hemingway, A. C. Nicholson, E. Brunner, and S. A. Stansfeld, “Low job control and risk of coronary heart disease in Whitehall II (prospective cohort) study,” BMJ, vol. 314, no. 7080, pp. 558–565, 1997.
[5] P. Bjørntorp, “Neuroendocrine perturbations as a cause of insulin resistance,” *Diabetes/Metabolism Research and Reviews*, vol. 15, no. 6, pp. 427–441, 1999.

[6] M. Kivimäki, S. T. Nyberg, G. D. Batty et al., “Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data,” *The Lancet*, vol. 380, no. 9852, pp. 1491–1497, 2012.

[7] S. T. Nyberg, E. I. Fransson, K. Heikkilä et al., “Job strain and cardiovascular disease risk factors: meta-analysis of individual-participant data from 47,000 men and women,” *PLoS One*, vol. 8, no. 6, article e67323, 2013.

[8] M. O. J. Grootaert, M. Moulis, L. Roth et al., “Muscle cell death, autophagy and senescence in atherosclerosis,” *Cardiovascular Research*, vol. 114, no. 4, pp. 622–634, 2018.

[9] A. C. Doran, N. Meller, and C. A. McNamara, “Role of smooth muscle cells in the initiation and early progression of atherosclerosis,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 28, no. 5, pp. 812–819, 2008.

[10] P. Wang, T. Y. Xu, Y. F. Guan et al., “Vascular smooth muscle cell apoptosis is an early trigger for hypothyroid atherosclerosis,” *Cardiovascular Research*, vol. 102, no. 3, pp. 448–459, 2014.

[11] L. Mulrane, S. F. McGee, W. M. Gallagher, and D. P. O’Connor, “miRNA dysregulation in breast cancer,” *Cancer Research*, vol. 73, no. 22, pp. 6554–6562, 2013.

[12] N. J. Leeper and L. Maegdefessel, “Non-coding RNAs: key regulators of smooth muscle cell fate in vascular disease,” *Cardiovascular Research*, vol. 114, no. 4, pp. 611–621, 2018.

[13] F. N. Salloum, C. Yin, and R. C. Kukreja, “Role of microRNAs in cardiac preconditioning,” *Journal of Cardiovascular Pharmacology*, vol. 56, no. 6, pp. 581–588, 2010.

[14] Q. Tang, H. Zhong, F. Xie, J. Xie, H. Chen, and G. Yao, “Expression of miR-106b-25 induced by salvianolic acid B inhibits epithelial-to-mesenchymal transition in HK-2 cells,” *European Journal of Pharmacology*, vol. 741, pp. 97–103, 2014.

[15] J. Krol, I. Loedige, and W. Filipowicz, “The widespread regulation of microRNA biogenesis, function and decay,” *Nature Reviews Genetics*, vol. 11, no. 9, pp. 597–610, 2010.

[16] D. Yu, H. S. Shin, Y. S. Lee, and Y. C. Lee, “miR-106b modulates cancer stem cell characteristics through TGF-β/Smad signaling in CD44-positive gastric cancer cells,” *Laboratory Investigation*, vol. 94, no. 12, pp. 1370–1381, 2014.

[17] L. Poliseno, L. Salmena, L. Riccardi et al., “Identification of the miR-106b−25 microRNA cluster as a proto-oncogenic PTEN−targeting intron that cooperates with its host gene MCM7 in transformation,” *Science Signaling*, vol. 3, no. 117, article ra29, 2010.

[18] M. Särközy, Z. Kahán, and T. Csontr, “A myriad of roles of miR-25 in health and disease,” *Oncotarget*, vol. 9, no. 30, pp. 21580–21612, 2018.

[19] S. A. Clayton, S. W. Jones, M. Kurowska-Stolarska, and A. R. Clark, “The role of microRNAs in glucocorticoid action,” *The Journal of Biological Chemistry*, vol. 293, no. 6, pp. 1865–1874, 2018.

[20] A. R. Kuhn, K. Schlauch, R. Lao, A. J. Halayko, W. T. Gerthoffer, and C. A. Singer, “MicroRNA expression in human airway smooth muscle cells: role of miR-25 in regulation of airway smooth muscle phenotype,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 42, no. 4, pp. 506–513, 2010.

[21] X. Feng, J. Jiang, S. Shi, H. Xie, L. Zhou, and S. Zheng, “Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway,” *International Journal of Oncology*, vol. 49, no. 6, pp. 2600–2610, 2016.

[22] Z. Chen, Y. Wu, Q. Meng, and Z. Xia, “Elevated microRNA-25 inhibits cell apoptosis in lung cancer by targeting RGS3,” *In Vitro Cellular & Developmental Biology Animal*, vol. 52, no. 1, pp. 62–67, 2016.

[23] C. Wahliquist, D. Jeong, A. Rojas-Muñoz et al., “Inhibition of miR-25 improves cardiac contractility in the failing heart,” *Nature*, vol. 508, no. 7497, pp. 531–535, 2014.

[24] Q. Liu, Y. Wang, T. Yang, and W. Wei, “Protective effects of miR-25 against hypoxia/reoxygenation-induced fibrosis and apoptosis of H9c2 cells,” *International Journal of Molecular Medicine*, vol. 38, no. 4, pp. 1225–1234, 2016.

[25] Y. Fu, Y. Zhang, Z. Wang et al., “Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy,” *American Journal of Nephrology*, vol. 32, no. 6, pp. 581–589, 2010.

[26] T. Wu, W. Chen, D. Kong et al., “miR-25 targets the modulator of apoptosis 1 gene in lung cancer,” *Carcinogenesis*, vol. 36, no. 8, pp. 925–935, 2015.

[27] J. B. Fan, W. Liu, X. H. Zhu et al., “MicroRNA-25 targets PKCζ and protects osteoblastic cells from dexamethasone via activating AMPK signaling,” *Oncotarget*, vol. 8, no. 2, pp. 3226–3236, 2017.

[28] L. K. Harris, R. J. Keogh, M. Wareing et al., “Invasive trophoblasts stimulate vascular smooth muscle cell apoptosis by a Fas ligand-dependent mechanism,” *The American Journal of Pathology*, vol. 169, no. 5, pp. 1863–1874, 2006.

[29] A. G. Vouyouka, L. Lin, and M. D. Basson, “Pressure and endothelial coculture upregulate mycotic Fas-FasL pathway and induce apoptosis by way of direct and paracrine mechanisms,” *American Journal of Surgery*, vol. 190, no. 5, pp. 780–786, 2005.

[30] G. Horvath, A. Torbati, G. E. Conner, M. Salathe, and A. Wanner, “Systemic ovalbumin sensitization downregulates norepinephrine uptake by rabbit aortic smooth muscle cells,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 27, no. 6, pp. 746–751, 2002.

[31] J. S. Lee, K. E. Kypreos, and G. E. Sonenshein, “Synchronization of cultured vascular smooth muscle cells following reversal of quiescence induced by treatment with the antioxidant N-acetylcysteine,” *Experimental Cell Research*, vol. 239, no. 2, pp. 447–453, 1998.

[32] J. Zhao, G. J. Pettigrew, J. Thomas et al., “Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac myocytes in vitro and in vivo,” *Basic Research in Cardiology*, vol. 97, no. 5, pp. 348–358, 2002.

[33] S. Sharma, J. Liu, J. Wei, H. Yuan, T. Zhang, and N. H. Bishophor, “Repression of miR-142 by p300 and MAPK is required for survival signalling via gp130 during adaptive hypertrophy,” *EMBO Molecular Medicine*, vol. 4, no. 7, pp. 617–632, 2012.

[34] A. Wilson, L. A. Shehadeh, H. Yu, and K. A. Webster, “Age-related molecular genetic changes of murine bone marrow mesenchymal stem cells,” *BMC Genomics*, vol. 11, no. 1, p. 229, 2010.

[35] H. Shi, L. Chen, H. Wang et al., “Synergistic induction of miR-126 by hypoxia and HDAC inhibitors in cardiac...
myocytes,” *Biochemical and Biophysical Research Communications*, vol. 430, no. 2, pp. 827–832, 2013.

[36] Y. Zhang, Z. Peng, Y. Zhao, and L. Chen, “MicroRNA-25 inhibits cell apoptosis of human gastric adenocarcinoma cell line AGS via regulating CCNE1 and MYC,” *Medical Science Monitor*, vol. 22, pp. 1415–1420, 2016.

[37] E. Zoni, G. van der Horst, A. F. van de Merbel et al., “miR-25 modulates invasiveness and dissemination of human prostate cancer cells via regulation of \( \alpha_v \) and \( \alpha_6 \)-integrin expression,” *Cancer Research*, vol. 75, no. 11, pp. 2326–2336, 2015.

[38] L. A. Kubasiak, O. M. Hernandez, N. H. Bishopric, and K. A. Webster, “Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 20, pp. 12825–12830, 2002.

[39] H. Li, X. Zhu, J. Zhang, and J. Shi, “MicroRNA-25 inhibits high glucose-induced apoptosis in renal tubular epithelial cells via PTEN/AKT pathway,” *Biomedicine & Pharmacotherapy*, vol. 96, pp. 471–479, 2017.

[40] K. O. Tan, K. M. L. Tan, S. L. Chan et al., “MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains,” *The Journal of Biological Chemistry*, vol. 276, no. 4, pp. 2802–2807, 2001.

[41] T. M. Paravicini and R. M. Touyz, “NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities,” *Diabetes Care*, vol. 31, Supplement 2, pp. S170–S180, 2008.

[42] P. S. Gill and C. S. Wilcox, “NADPH oxidases in the kidney,” *Antioxidants & Redox Signaling*, vol. 8, no. 9-10, pp. 1597–1607, 2006.

[43] S. H. Tan, H. Ida, B. C. Goh, W. Hsieh, M. Loh, and Y. Ito, “Analyses of promoter hypermethylation for RUNX3 and other tumor suppressor genes in nasopharyngeal carcinoma,” *Anticancer Research*, vol. 26, no. 6B, pp. 4287–4292, 2006.

[44] Z. Wang, N. Wang, P. Liu et al., “MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin,” *Oncotarget*, vol. 5, no. 16, pp. 7013–7026, 2014.

[45] C. Caiazza and M. Mallardo, “The roles of miR-25 and its targeted genes in development of human cancer,” *MicroRNA*, vol. 5, no. 2, pp. 113–119, 2016.

[46] S. Baksh, S. Tommasi, S. Fenton et al., “The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death,” *Molecular Cell*, vol. 18, no. 6, pp. 637–650, 2005.

[47] M. D. Vos, A. Dallol, K. Eckfeld et al., “The RASSF1A tumor suppressor activates Bax via MOAP-1,” *The Journal of Biological Chemistry*, vol. 281, no. 8, pp. 4557–4563, 2006.